Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial.
| Author | |
|---|---|
| Abstract |
:
Currently, there are no randomized trials on the effect of antiangiogenic therapy in patients with esophageal squamous cell carcinoma (ESCC). The following study investigated the efficacy and safety of anlotinib in patients with advanced ESCC who were previously treated with chemotherapy. |
| Year of Publication |
:
2021
|
| Journal |
:
Cancer medicine
|
| Volume |
:
10
|
| Issue |
:
5
|
| Number of Pages |
:
1681-1689
|
| URL |
:
https://doi.org/10.1002/cam4.3771
|
| DOI |
:
10.1002/cam4.3771
|
| Short Title |
:
Cancer Med
|
| Download citation |
